Covered recipient · General Payments record
NILESH ISHWARLAL LODHIA
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$154,569.61
224 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $107,938.00 | 32 |
| Honoraria | $17,522.50 | 7 |
| Travel and Lodging | $17,234.99 | 35 |
| Food and Beverage | $6,169.12 | 148 |
| Consulting Fee | $5,705.00 | 2 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $84,563.33 | 74 |
| ABBVIE INC. | $33,271.84 | 60 |
| Celltrion USA Inc. | $25,219.95 | 43 |
| PFIZER INC. | $10,770.72 | 27 |
| Lilly USA, LLC | $330.58 | 6 |
| Cook Medical LLC | $139.33 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $113.67 | 6 |
| Regeneron Healthcare Solutions, Inc. | $47.82 | 2 |
| Phathom Pharmaceuticals, Inc. | $47.70 | 2 |
| Janssen Scientific Affairs, LLC | $23.41 | 1 |
| GENZYME CORPORATION | $22.61 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.65 | 1 |
Page 2 of 5; records 51–100 of 224 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
NILESH ISHWARLAL LODHIA
NPI 1922264654 · CMS profile ID 313976
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
CHARLOTTE, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 5; records 51–100 of 224 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1922264654?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- NILESH ISHWARLAL LODHIA, NPI 1922264654, CMS profile ID 313976. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 224 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922264654?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). NILESH ISHWARLAL LODHIA, NPI 1922264654, CMS profile ID 313976. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 224 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922264654?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- NILESH ISHWARLAL LODHIA, NPI 1922264654, CMS profile ID 313976, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 224 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1922264654?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
224 matching records · $154,569.61 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 224.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Celltrion USA Inc. | $23.12 | 10/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250826830 | CMS |
| Janssen Biotech, Inc. | $28.69 | 10/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175068308 | CMS |
| ABBVIE INC. | $4,025.00 | 10/17/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202318058 | CMS |
| ABBVIE INC. | $2,875.00 | 10/17/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202318060 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $19.52 | 10/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223853223 | CMS |
| Celltrion USA Inc. | $125.00 | 10/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250826828 | CMS |
| Phathom Pharmaceuticals, Inc. | $23.05 | 10/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1219263483 | CMS |
| ABBVIE INC. | $18.02 | 10/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202318056 | CMS |
| Janssen Biotech, Inc. | $5,250.00 | 10/11/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175058469 | CMS |
| Janssen Biotech, Inc. | $5,250.00 | 10/11/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175067493 | CMS |
| ABBVIE INC. | $99.27 | 10/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202318054 | CMS |
| ABBVIE INC. | $17.72 | 10/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202318050 | CMS |
| ABBVIE INC. | $10.00 | 10/08/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202318052 | CMS |
| Janssen Biotech, Inc. | $1,047.60 | 10/08/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175058447 | CMS |
| Janssen Biotech, Inc. | $147.41 | 10/08/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175060037 | CMS |
| Janssen Biotech, Inc. | $97.91 | 10/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175065853 | CMS |
| Janssen Biotech, Inc. | $1,007.55 | 10/08/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175072073 | CMS |
| Janssen Biotech, Inc. | $750.00 | 10/07/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175062116 | CMS |
| Celltrion USA Inc. | $3,260.00 | 10/06/2025 | Honoraria | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250826810 | CMS |
| Celltrion USA Inc. | $36.44 | 10/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250826812 | CMS |
| Celltrion USA Inc. | $15.35 | 10/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250826814 | CMS |
| Celltrion USA Inc. | $8.87 | 10/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250826816 | CMS |
| Celltrion USA Inc. | $42.80 | 10/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250826818 | CMS |
| Celltrion USA Inc. | $3,667.50 | 10/06/2025 | Honoraria | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250826820 | CMS |
| Celltrion USA Inc. | $486.78 | 10/06/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250826822 | CMS |
| Celltrion USA Inc. | $56.00 | 10/06/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250826824 | CMS |
| Celltrion USA Inc. | $7.00 | 10/06/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250826826 | CMS |
| ABBVIE INC. | $20.13 | 10/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202318048 | CMS |
| ABBVIE INC. | $4.84 | 10/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202318046 | CMS |
| Janssen Biotech, Inc. | $21.35 | 10/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175063268 | CMS |
| ABBVIE INC. | $120.00 | 10/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202318042 | CMS |
| ABBVIE INC. | $818.55 | 10/02/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202318044 | CMS |
| PFIZER INC. | $16.93 | 10/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229209568 | CMS |
| Celltrion USA Inc. | $1,222.50 | 09/30/2025 | Honoraria | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250826808 | CMS |
| ABBVIE INC. | $23.43 | 09/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202318040 | CMS |
| ABBVIE INC. | $4,025.00 | 09/25/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202318038 | CMS |
| ABBVIE INC. | $28.17 | 09/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202318036 | CMS |
| Celltrion USA Inc. | $125.00 | 09/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250826806 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $22.11 | 09/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223875134 | CMS |
| Janssen Biotech, Inc. | $33.87 | 09/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175062965 | CMS |
| Celltrion USA Inc. | $21.84 | 09/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250826804 | CMS |
| Celltrion USA Inc. | $21.84 | 09/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250826802 | CMS |
| Celltrion USA Inc. | $21.84 | 09/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250826800 | CMS |
| ABBVIE INC. | $124.99 | 09/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202318032 | CMS |
| ABBVIE INC. | $625.95 | 09/11/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202318034 | CMS |
| ABBVIE INC. | $22.62 | 09/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202318030 | CMS |
| PFIZER INC. | $7.05 | 09/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229425152 | CMS |
| ABBVIE INC. | $13.17 | 09/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202318028 | CMS |
| ABBVIE INC. | $4.94 | 09/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202318026 | CMS |
| Janssen Biotech, Inc. | $10.75 | 08/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175065877 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $153,955.49 | 119 |
| PY2024 | Principal investigator | $94,331.65 | 34 |
| PY2023 | Principal investigator | $88,969.66 | 26 |
| PY2022 | Principal investigator | $129,281.29 | 31 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
119 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,115.52 | 12/19/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651981 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,115.00 | 12/19/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651983 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,916.80 | 12/19/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651985 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,500.00 | 12/04/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211683850 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,000.00 | 12/04/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211683852 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $9,000.00 | 12/04/2025 | Non-covered Recipient Entity Wake Forest University Health Sciences | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211683854 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,192.32 | 11/13/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651979 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.98 | 10/27/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651987 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 10/27/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651989 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.60 | 10/27/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651991 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.62 | 10/27/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651993 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,660.80 | 10/22/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651975 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $210.34 | 10/14/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651973 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.14 | 10/10/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651971 |
| Principal investigator 1 | ABBVIE INC. | $1,304.39 | 10/09/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202404330 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.32 | 09/24/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651955 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 09/24/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651957 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $511.00 | 09/24/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651959 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.62 | 09/24/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651961 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.62 | 09/24/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651963 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.62 | 09/24/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651965 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.62 | 09/24/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651967 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $18.58 | 09/24/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651969 |
| Principal investigator 1 | ABBVIE INC. | $2,500.00 | 09/05/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202510166 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 09/04/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202509148 |
| Principal investigator 1 | ABBVIE INC. | $3,865.00 | 09/04/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202509224 |
| Principal investigator 1 | ABBVIE INC. | $12,500.00 | 09/04/2025 | Non-covered Recipient Entity ATRIUM HEALTH FOUNDATION | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) | No dispute reported | 06/30/2026 | 1202509226 |
| Principal investigator 1 | ABBVIE INC. | $556.37 | 08/26/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202404308 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 08/26/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651945 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.24 | 08/26/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651947 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.24 | 08/26/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651949 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.24 | 08/26/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651951 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.24 | 08/26/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651953 |
| Principal investigator 1 | ABBVIE INC. | $191.02 | 08/20/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202505213 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 08/19/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202404304 |
| Principal investigator 1 | ABBVIE INC. | $4,605.87 | 08/06/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202502258 |
| Principal investigator 1 | ABBVIE INC. | $13,000.00 | 08/06/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202502779 |
| Principal investigator 1 | ABBVIE INC. | $1,623.68 | 08/05/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202404288 |
| Principal investigator 1 | ABBVIE INC. | $1,953.67 | 08/05/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202404297 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,000.00 | 07/30/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651929 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,500.00 | 07/30/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651933 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9,000.00 | 07/30/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651935 |
| Principal investigator 1 | ABBVIE INC. | $5,000.00 | 07/22/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202404281 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,500.00 | 07/14/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651927 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,500.00 | 07/14/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651931 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $500.00 | 07/14/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651937 |
| Principal investigator 1 | ABBVIE INC. | $126.50 | 07/02/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202404269 |
| Principal investigator 1 | ABBVIE INC. | $52.00 | 07/02/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202496375 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 07/01/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651939 |
| Principal investigator 1 | Celgene Corporation | $4,700.00 | 06/12/2025 | Covered Recipient Teaching Hospital Atrium Health Cabarrus | Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1222306349 |
| Principal investigator 1 | ABBVIE INC. | $146.74 | 06/03/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202404253 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 06/01/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651943 |
| Principal investigator 1 | ABBVIE INC. | $3,465.00 | 05/20/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202485515 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.89 | 05/07/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651917 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.79 | 05/07/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651919 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $147.49 | 05/07/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651921 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $147.49 | 05/07/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651923 |
| Principal investigator 1 | ABBVIE INC. | $1,304.39 | 05/06/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202404241 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 05/01/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651925 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $225.00 | 04/21/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651903 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,600.00 | 04/21/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651905 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $210.34 | 04/21/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651907 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.21 | 04/21/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651909 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $161.00 | 04/21/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651911 |
| Principal investigator 1 | Celgene Corporation | $8,165.00 | 04/10/2025 | Covered Recipient Teaching Hospital Atrium Health Cabarrus | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1222306275 |
| Principal investigator 1 | Celgene Corporation | $500.00 | 04/10/2025 | Covered Recipient Teaching Hospital Atrium Health Cabarrus | A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1222306325 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 04/01/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651913 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 03/25/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY | M21-446 - Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202465844 |
| Principal investigator 1 | ABBVIE INC. | $6,202.00 | 03/20/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202404214 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 03/20/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY | M23-703 - A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202465323 |
| Principal investigator 1 | ABBVIE INC. | $95.00 | 03/13/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY | M21-446 - Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202463711 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 03/11/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202404207 |
| Principal investigator 1 | ABBVIE INC. | $1,257.82 | 03/06/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202404196 |
| Principal investigator 1 | ABBVIE INC. | $59.46 | 03/06/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | M16-066 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202404203 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 03/01/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651915 |
| Principal investigator 1 | ABBVIE INC. | $2,526.00 | 02/06/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY | M21-446 - Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202449435 |
| Principal investigator 1 | ABBVIE INC. | $5,130.56 | 02/05/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202404176 |
| Principal investigator 1 | ABBVIE INC. | $6,207.24 | 02/05/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | M16-066 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202404181 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 02/01/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651941 |
| Principal investigator 1 | ABBVIE INC. | $3,253.00 | 01/29/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY | M21-446 - Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202441877 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $128.26 | 01/27/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651887 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 01/27/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651889 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,022.00 | 01/27/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651891 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.05 | 01/27/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651893 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.05 | 01/27/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651895 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.05 | 01/27/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651897 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.05 | 01/27/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651899 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.55 | 01/27/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651901 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $70.00 | 01/24/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651977 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.01 | 01/23/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651839 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $143.55 | 01/23/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651841 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.98 | 01/23/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651843 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $244.84 | 01/23/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651845 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $27.14 | 01/23/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651847 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20.65 | 01/23/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651849 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.33 | 01/23/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651851 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14.51 | 01/23/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651853 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $33.12 | 01/23/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651855 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.57 | 01/23/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651857 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.24 | 01/23/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651859 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $37.57 | 01/23/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651861 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $71.76 | 01/23/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651863 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $341.63 | 01/23/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651865 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.33 | 01/23/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651869 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.33 | 01/23/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651871 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.33 | 01/23/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651873 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.33 | 01/23/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651875 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.33 | 01/23/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651877 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.40 | 01/22/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651867 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $398.00 | 01/21/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651995 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,040.00 | 01/21/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651997 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.00 | 01/21/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651999 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.00 | 01/21/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220652001 |
| Principal investigator 1 | ABBVIE INC. | $717.88 | 01/07/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn Disease (CD) | No dispute reported | 06/30/2026 | 1202404156 |
| Principal investigator 1 | ABBVIE INC. | $170.37 | 01/02/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH CABARRUS | M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202404152 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 01/01/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651879 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $50.00 | 01/01/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651881 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 01/01/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651883 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $28.00 | 01/01/2025 | Non-covered Recipient Entity Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220651885 |